Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir

Journal of Clinical Pharmacology

Volumn 45, Issue 11, 2005, Pages 1250-1258

  Lin, Chin Chung ^a   Xu, Christine ^a   Teng, Alice ^a   Yeh, Li Tain ^a   Peterson, Janet ^a  

^a Valeant Pharmaceuticals International   (United States)

Author keywords

Adefovir dipivoxil; Antiviral; Hepatitis B; Pharmacokinetics; Pradefovir

Indexed keywords

ADEFOVIR; PHOSPHONIC ACID DERIVATIVE; PRADEFOVIR; PRODRUG; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; FOOD DRUG INTERACTION; FOOD INTAKE; GLOMERULUS FILTRATION; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; METABOLIC CLEARANCE RATE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION; VOLUNTEER; VOMITING;

ADENINE; ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; DIETARY FATS; DOUBLE-BLIND METHOD; FOOD-DRUG INTERACTIONS; HUMANS; MALE; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PRODRUGS;

EID: 27244446626     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005280644     Document Type: Article

References (28)

1. Heijtink, RA, De Wilde GA, Krunining J, et al. Inhibitory effect of 9-2-phosphonylmethoxyethyladenine (PMEA) on human and duck hepatitis B virus infection. Antivir Res. 1993;21:141-142.
2. Heijtink RA, Kruining J, De Wilde GA, Balzarini J, De Clercq E, Schalm SW Inhibitory effect of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother. 1994;38:2180-2182.
3. Merta A, Vesely J, Votruba I, Rosenberg I, Holy A. Phosphorylation of acyclic nucleotide analogues HPMPA and PMEA in L1210 mouse leukemic cell extracts. Neoplasma. 1990;37:111-120.
4. Balzarini J, Hao Z, Herdewijn P, Johns DG, De Clercq E. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2- phosphonylmethoxyethyl) adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci. 1991;88:1499-1503.
5. Cundy KC, Shaw JP, Lee W. Oral, subcutaneous and intramuscular bioavailability of the antiviral nucleotide analog 9-(2-phosphonylmethoxy-ethyl) adenine (PMEA) in cynomolgus monkeys. Antimicrob Agents Chemother. 1994;38:365-368.
6. Cundy KC, Barditch-Crovo P, Walker RE, et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type I-infected patients. Antimicrob Agents Chemother. 1995;39:2401-2405.
7. Starrett JE, Mansuri MM, Martin JC, Tortolani DR, Bronson JJ. European Patent 481, 214, A1. April 1992.
8. Palu SS, Rassu M, Parolin C, Balzarini J, De Clercq E. Cellular uptake of phosphonylmethoxyalkylpurine derivatives. Antimicrob Agents Chemother. 1991;16:115-119.
9. Heathcote E, Jeffers L, Wright T. Loss of serum HBV DNA and HbeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies. Hepatology. 1998;28(suppl):317A.
10. Heathcote EJ, Jeffers L, Perrilo R, et al. Serum HBV DNA suppression and seroconversion following long-term adefovir dipivoxil therapy in chronic hepatitis B patients. Hepatology. 2001;34:316A.
11. Food and Drug Administration. Adefovir dipivoxil for the treatment of chronic hepatitis B. FDA Advisory Committee Brief Document. July 5, 2002. NDA 21-449.
12. Lin CC, Yeh LT, Vitarella D, Hong Z, Erion MD. Pradefovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys. Antiviral Chem Chemother. 2004;15:307-316.
13. Steinijans VW, Hauschke D. Update on the statistical analysis of bioequivalence studies. Int J Pharmacol Ther Toxicol. 1990;28:105-110.
14. Giesbrecht FG, Burns JC. Two-stage analysis based on a mixed model: large sample asymptotic theory and small-sample simulation results. Biometrics. 1985;41:477-486.
15. Satterthwaite FE. Synthesis of variance. Psychometrika. 1941;6:309-316.
16. Satterthwaite FE. Biometrics Bulletin. 1946;2:110-114.
17. Starrett JE, Tortolani DR, Russel J. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonylmethoxyethyl)-adenine (PMEA). J Med Chem. 1994;37:1857-1864.
18. Shaw JP, Cundy KC. Biological screens of PMEA prodrugs. Pharm Res. 1993;10(suppl):S294.
19. Annaert P, Kinget R, Naesens L. Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in-vitro cell culture system of the intestinal mucosa (Caco-2). Pharm Res. 1970;14:492-496.
20. Marcellin P, Chang T, Lim S, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-816.
21. Naesens L, Balzarini J, Bisshofberger N. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonyl- methoxyethyl)adenine. Antimicrob Agents Chemother. 1996;40:22-28.
22. Barditch-Crovo P, Toole J, Hendrix CW, Cundy C, Ebeling D, Jaffe HS, Lietman PS. 1997. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)- phosphonylmethoxyethyl] adenine) in HIV-infected patients. J Infectious Disease. 1997;176:406-413.
23. Cihlar T, Rosenberg I, Votruba I, Holy A. Transport of 9-(2-phosphonylmethoxyethyl) adenine across plasma membrane of HeLa S3 cells I protein mediated. Antimicrob Agents Chemother. 1995;39:117-124.
24. Naesens L, Balzarini J, De Clercq E. Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine. Drug Met Dispos. 1992;20:747-752.
25. Erion M, Reddy K, Boyer S, et al. Design, synthesis, and characterization of a series of cytochrome P450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph9onate-based drugs to the liver. J Am Chem Soc. 2004;126:5154-5163.
26. Erion M, van Poelje P, MacKenna D, et al. Liver-targeting drug delivery using HepDirect prodrugs. J Pharmacol Exp Therap. 2005;312:554-560.
27. Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Met Dispos. 1999;27:161-166.
28. De Kanter R, De Jager MH, Draaisma AL, et al. Drug-metabolizing activity of human and rat liver, lung, kidney and intestine slices. Xenobiotica. 2002;32:349-362.